All fields are required.

Close Appointment form

A phase 3 study for chikungunya vaccine after passing midstage test

  • Home
  • A phase 3 study for chikungunya vaccine after passing midstage test
A phase 3 study for chikungunya vaccine after passing midstage test
A phase 3 study for chikungunya vaccine after passing midstage test

No Comments

A phase 3 study for chikungunya vaccine after passing midstage test

The chikungunya vaccine, known as MV-CHIK, hit its primary goal in the phase 2 trial, and Themis is now eyeing a move into phase 3. The company based its chikungunya shot on its measles vector platform, licensed from Institut Pasteur.

  • Share This

Related Posts

Submit a comment

Your email address will not be published. Required fields are marked *

Leave a Reply

You may use these HTML tags and attributes:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>